CF PHARMTECH (02652) saw its shares rise more than 17%. At the time of writing, the stock was up 16.43%, trading at HK$26.78, with a turnover of HK$12.2058 million. On the news front, on March 13, CF PHARMTECH announced that the Investigational New Drug (IND) application for ICF001, its self-developed inhaled powder for treating Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), has been formally accepted by China's National Medical Products Administration (NMPA). ICF001 is a chemical drug categorized as a Class 2.1 improved new drug. This marks the company's second inhaled improved innovative drug to receive acceptance, following ICF004, signaling that its innovative R&D pipeline in high-end respiratory formulations is accelerating into a harvest phase. ICF001 is an innovative inhaled powder that utilizes a prodrug mechanism to achieve long-lasting effects. Drugs in this class have established clear clinical value and demonstrated blockbuster potential in related rare and severe pulmonary diseases. Notably, there are currently no specific therapeutics approved in China for PH-ILD. The rapid advancement of ICF001 positions it to potentially become the first inhaled drug approved in China for treating PH-ILD, filling a critical market gap and offering new hope to hundreds of thousands of patients globally.